UTHR
USDUnited Therapeutics Corporation Common Stock
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$432.750
Máximo
$440.000
Mínimo
$430.020
Volumen
0.35M
Fundamentos de la Empresa
Capitalización de Mercado
18.8B
Industria
Drug Manufacturers - Specialty & Generic
País
United States
Estadísticas de Negociación
Volumen Promedio
0.79M
Bolsa
NMS
Moneda
USD
Rango de 52 Semanas
Noticias Relacionadas
United Therapeutics Corporation to Present at Upcoming Investor Conferences
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions at two upcoming
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease
Ongoing EXPAND Study is the First Clinical Trial to Evaluate Xenotransplantation in End-Stage Renal Disease United Therapeutics Corporation (Nasdaq: UTHR) today announced the first clinical xenotransplantation in its
HC Wainwright & Co. Maintains Buy on United Therapeutics, Raises Price Target to $525
HC Wainwright & Co. analyst Andrew S. Fein maintains United Therapeutics with a Buy and raises the price target from $500 to $525.
RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $587
RBC Capital analyst Lisa Walter maintains United Therapeutics with a Outperform and raises the price target from $569 to $587.
Wells Fargo Maintains Equal-Weight on United Therapeutics, Raises Price Target to $423
Wells Fargo analyst Benjamin Burnett maintains United Therapeutics with a Equal-Weight and raises the price target from $414 to $423.
United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quarter ended September 30, 2025, driven by continued year-over-year revenue growth in key
United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. A press release detailing the quarterly
Acciones Relacionadas
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.